Loading clinical trials...
Loading clinical trials...
A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28-Day Oral Administration of AZD5069 Twice Daily in Patients With Bronchiectasis
Conditions
Interventions
AZD5069
Placebo
Locations
15
Czechia
Research Site
Ostrava, Czechia
Research Site
Prague, Czechia
Research Site
Krakow, Poland
Research Site
Lodz, Poland
Research Site
Warsaw, Poland
Research Site
Hull, East Yorkshire, United Kingdom
Start Date
February 1, 2011
Primary Completion Date
February 1, 2012
Completion Date
February 1, 2012
Last Updated
October 8, 2015
NCT07484243
NCT06166056
NCT02779478
NCT07274631
NCT06992661
NCT07077486
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions